Metafolin in combined oral contraceptives – investments in reproductive welfare. World news: modern contraception – opportunity of pregravidarum preparing

Authors

  • Т. В. Галина Peoples’ Friendship University of Russia, Russian Federation

DOI:

https://doi.org/10.18370/2309-4117.2013.11.82-88

Keywords:

folic acid, combined oral contraceptives, pregnancy, Metafolin

Abstract

This article is a review of the material on the key studies that demonstrated in women of reproductive age, especially considering pregnancy the efficacy and safety of oral contraceptives containing ethinylestradiol and drospirenone combined with the active form of folic acid. Such combination provide increased folate levels in red blood cells and in plasma, reduced homocysteine levels in the blood plasma, thereby significantly reduce the probability of abnormal fetus development. The expediency of receiving data combined drugs proved not only for contraception, but also for pregravidarum preparing – to normalize the folate status of women requires minimum 16 weeks of exogenous folate intake, and the probability of pregnancy is very high right after the withdrawal combined oral contraceptives.

Author Biography

Т. В. Галина, Peoples’ Friendship University of Russia

Department of Obstetrics and Gynecology with course of Perinatology

References

  1. Pitkin RM Folate and neural tube defects // Amer. J. Clin. Nutr. – 2007. – Vol. 85. – P. 285S–288S.
  2. Cragan JD, Roberts HE, Edmonds LD et al. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis: United States, 1985–1994 // MMWR CDC Surveill Summ. – 1995. – Vol. 44. – P. 1–13.
  3. Botto LD, Moore CA, Khoury MJ, Erickson JD Neural-tube defects // N Engl. J Med. – 1999. – Vol. 341. – P. 1509–1519.
  4. Cheschier N ACOG practice bulletin. Neural tube defects. Number 44, July 2003 (Replaces committee opinion number 252, March 2001) // Int J Gynecol. Obstet. – 2003. – Vol. 83; №1. – P. 123–133.
  5. De Jong-Van den Berg LT, Hernandez-Diaz S, Werler MM, Louik C, Mitchell AA Trends and predictors of folic acid awareness and periconceptional use in pregnant women // Am J Obstet. Gynecol. – 2005. – Jan. Vol. 192; №1. – P. 121–128.
  6. Ouyang L, Grosse SD, Armour BS, Waitzman NJ Health care expenditures of children and adults with spina bifi da in a privately insured US population // Birth Defects Res A Clin Mol Teratol. – 2007. – Vol. 79. – P. 552–558.
  7. Centers for Disease Control and Prevention Recommendations for the use of folic acid to reduce the number of cases of spina bifi da and other neural tube defects // MMWR Morb Mortal Wkly Rep. – 1992. – Vol. 41 (RR-14).
  8. Daly LE, Kirke PN, Molloy A et al. Folate levels and neural tube defects. Implications for prevention // JAMA. – 1995. – Vol. 274. – P. 1698–1702.
  9. Burke B, Daniel KL, Latimer A et al. Preventing neural tube birth defects: a prevention model and resource guide. Atlanta, GA: Centers for Disease Control and Prevention, 2009.
  10. US Preventive Services Task Force Folic acid for the prevention of neural tube defects: US Preventive Services Task Force Recommendation Statement // Ann Intern Med. – 2009. – Vol. 150. – P. 626–631.
  11. Yang QH, Carter HK, Mulinare J et al. Raceethnicity diff erences in folic acid intake in women of childbearing age in the United States after folic acid fortifi cation: fi ndings from the National Health and Nutrition Examination Survey, 2001–2002 // Am J Clin Nutr. – 2007. – Vol. 85. – P. 1409–1416.
  12. Centers for Disease Control and Prevention Use of supplements containing folic acid among women of childbearing age — United States, 2007 // MMWR Morb Mortal Wkly Rep. – 2008. – Vol. 57. – P. 5–8.
  13. Colli E, Tong D, Penhallegon R, Parazzini F Reasons for contraceptive discontinuation in women 20–39 years old in New Zealand // Contraception. – 1999. – Vol. 59. – P. 227–231.
  14. Chmura A, Szacilowski K, Stasicka Z Nitric oxide, 2006.
  15. Ray JG, Laskin CA Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: A systematic review // Placenta. – 1999. – Sep. Vol. 20; №7. – P. 519–529.
  16. Folic acid fortification prevents neural tube defects and may also reduce cancer risks. Margaretha Jägerstad Acta Pædiatrica, 2012 // Foundation Acta Pædiatrica. – 2012. – Vol. 101. – P. 1007–1012.
  17. USPSTF Ann Intern Med. – 2009. – Vol. 150; №9. – P. 626–631.
  18. VA/DoD clinical practice guideline for management of pregnancy. – 2002 Oct (revised 2009).
  19. EUROCAT. – URL: www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIA.pdf.
  20. EUROCAT.– URL: www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIB.pdf31.
  21. Lamers Y Am J Clin Nutr. – 2006. – Vol. 84; №1. – P. 156–161.
  22. Bort StS et al. Сontraception. – 2012. – Vol. 85. – P. 42–50.
  23. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM295228.pdf.
  24. Cronin M, Schellschmidt I, Dinger J Rate of pregnancy following use of drospirenone- and other progestin-containing oral contraceptive // Obstet. Gynecol. – 2009. – Vol. 114; №3. – P. 616–622.
  25. Diefenbach K, Trummer D, Ebert F, Lissy M, Rohde B, Blode H Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg coadministration // Eur J Contracept Reprod Health Care. – 2010. – Vol. 15; Suppl. 1. – P. 111–112.
  26. Food&Drug Administration Summary minutes: Advisory Committee for Reproductive Health Drugs meeting. – December 15, 2003.
  27. Dinger J, Minh TD, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen // Obstet. Gynecol. – 2011. – № 117. – P. 33–40.
  28. Stephan Bart Sr, Joachim Marr, Konstanze Diefenbach, Dietmar Trummer, Carole Sampson-Landers Contraception. – 85 (2012). – 42–50.
  29. Stenglin A van et al. Eur J Contracept reprod Health Care. – 2010. – Vol. 15; Suppl. 1. – P. 37–38.
  30. Stenglin A van et al. Еur J Contracept reprod Health Care. – 2010. – Vol. 15; Suppl. 1. – P. 112–113.
  31. Greiner T Vitamins and minerals for women: recent programs and intervention trials // Nutrition Research and Practice. – 2011. – Vol. 5; №1. – P. 3–10.
  32. Anttila L, Kunz M, Marr J Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive // Contraception. – 2009. – Vol. 80. – P. 445–451.
  34. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peña-Rosas JP Effects and safety of periconceptional folate supplementation for preventing birth defects // Cochrane Database Syst. Rev. – 2010. – Oct 6; (10): CD007950.
  35. Abrahams BS, Geschwind DH Advances in autism genetics: on the threshold of a new neurobiology // Nat. Rev. Genet. – 2008. – Vol. 9; №5. – P. 341–355.
  36. Arndt TL, Stodgell CJ, Rodier PM The teratology of autism // Int. J Dev Neurosci. – 2005. – Vol. 23; №2–3. – P. 189–199.
  37. Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tassone F, Hertz-Picciotto I Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) casecontrol study // Am J Clin. Nutr. – 2012. – Jul. Vol. 96; №1. – P. 80–89. – Epub 2012 May 30.
  38. Newschaffer CJ, Croen LA, Daniels J et al. The epidemiology of autism spectrum disorders // Annu Rev Public Health. – 2007. – Vol. 28. – P. 235–258.
  39. Preston-Martin S, Pogoda JM, Mueller BA, Lubin F, Modan B, Holly EA, Filippini G, Cordier S, Peris-Bonet R, Choi W, Little J, Arslan A Prenatal vitamin supplementation and pediatric brain tumors: huge international variation in use and possible reduction in risk // Childs Nerv. Syst. – 1998. – Oct. Vol. 14; №10. – P. 551–557.
  40. Preston-Martin S, Pogoda JM, Mueller BA, Lubin F, Holly EA, Filippini G, Cordier S, PerisBonet R, Choi W, Little J, Arslan A Prenatal vitamin supplementation and risk of childhood brain tumors // Int J Cancer Suppl. – 1998. – Vol. 11. – P. 17–22.
  41. Wien TN, Pike E, Wisloff T, Staff A, Smeland S, Klemp M Cancer risk with folic acid supplements: a systematic review and meta-analysis // BMJ Open. – 2012. – Vol. 2. – P. e000653.
  42. Bukowski R, Malone FD, Porter FT, Nyberg DA, Comstock CH, Hankins GD, Eddleman K, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study // PLoS Med. – 2009. – May 5. – Vol. 6; №5. – P. e1000061.
  43. Bodnar LM, Himes KP, Venkataramanan R, Chen J-Y et al. Maternal serum folate species in early pregnancy and risk of preterm birth // Am J Clin. Nutr. – 2010. – Oct. Vol. 92; №4. – P. 864–871.
  44. Marr J, Sampson-Landers C, Diefenbach K, Trummer D, Bart S, Blode H Folate and homocysteine levels after 24 weeks administration of YAZ + levomefolate calcium 0.451 mg // Eur J Contracept Reprod Health Care. – 2010. – Vol. 15; Suppl. 1. – P. 159.
  45. Spirichev VB Scientific rationale for vitamins use in the prevention and treatment. Message 1: The lack of vitamins in the diet of modern human: causes, consequences and correction // Nutrition. – 2010. – T. 79; No. 5. – P. 4–14.
  46. Maltseva LI, Pavlova TV Genetic aspects of preeclampsia // Practical medicine. – 2011. – № 6 (11).
  47. Zhuchenko LA Primary prevention of folate-dependent congenital malformations. The first Russian experience: Dissertation for the MD degree. – M., 2009. – P. 4.
  48. Zhuchenko LA Prevention of congenital malformations in fetus and newborn through the use of folic acid in pregravidarum period: rationale, methods, perspectives // Almanac of clinical medicine. – 2002. – № 5. – P. 185–191.
  49. Tsurcan SV Pregastational preparation of the couple as a population-wide programs for primary prevention of prenatal pathology in the Samara Region // Russian Journal of the obstetrician-gynecologist. – 2009. – № 5. – P. 9–14.
  50. Tsurcan SV Strategy of the population prophylaxis of congenital pathology // Kazan Med. Journal. – 2011. – T. 92; № 3. – P. 449–450.
  51. Strizhenok EA, Gudkov IV, Stratchounski LS Drugs use in pregnancy: results of a multicenter pharm-epidemiological studies // Clinical Microbiology and Antimicrobial Chemotherapy. – 2007. – T. 9; № 2. – P. 162–175.
  52. Radzinsky VE, Orazmuradova AA Early pregnancy // StatusPraesens. – 2009. – P. 363.

Downloads

Published

2013-11-16

How to Cite

Галина, Т. В. (2013). Metafolin in combined oral contraceptives – investments in reproductive welfare. World news: modern contraception – opportunity of pregravidarum preparing. REPRODUCTIVE ENDOCRINOLOGY, (11), 82–88. https://doi.org/10.18370/2309-4117.2013.11.82-88

Issue

No. 11 (2013)

Section

Contraception

License

Copyright (c) 2014 Т. В. Галина

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.